COVID-19 Vaccines: Regulatory Consortium Addresses Way Forward With Immunobridging Studies
Executive Summary
Drug regulators from five countries have outlined their joint expectations on the data companies must submit for the approval of next-generation COVID-19 vaccines if they opt for immunobridging studies instead of large-scale efficacy trials.
You may also be interested in...
US FDA Signals New COVID-19 Vaccines Could Be Authorized With Just Immunogenicity Studies
As FDA lowers some expectations on timing of booster shots, agency’s outgoing vaccine chief says second-generation COVID vaccines may be authorized without efficacy studies. Marion Gruber's conclusion was supported by many of her international regulatory peers during a WHO meeting.
EMA Considers How To Verify Potency Of Next-Generation COVID-19 Vaccines
Companies approaching the European Medicines Agency with their development plans for new COVID-19 vaccines are being asked to consider immunobridging studies if placebo-controlled trials are not feasible.
US FDA Sets Immunogenicity Bar High For Changes To COVID-19 Vaccines
Modified vaccines targeted at new SARS-CoV-2 variants must generate immune response rates not more than 10% below those of the original vaccine, agency says in one of a suite of guidances on medical product development to address variants.